This study demonstrates that over 6 weeks of treatment, patients with melancholic depression and medical comorbidity (MC) (specifically cardiovascular or endocrinological MC) had poorer treatment response and a worse functional outcome as opposed to their counterparts without MC. Interestingly, these effects were not related to various antidepressant treatment regimens.
...[Read more]‘ A Depressed Life ’ Category
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.
...[Read more]Research presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience (SfN) and the world’s largest source of emerging news about brain science and health, provides a better understanding of the brain, nervous system, and related disorders.
...[Read more]New research clarifies how neurotransmitters like norepinephrine, serotonin, and dopamine, are regulated – a finding that may help fine-tune therapies for depression. Current drugs for depression target the regulatory process for neurotransmitters, and while effective in some cases, do not appear to work in other cases.
...[Read more]Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), has announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.
...[Read more]A team of researchers from Michigan State University and the University of Cincinnati have been awarded a $6.2 million Morris K. Udall Center of Excellence for Parkinson’s disease grant. The grant, from the National Institute for Neurological Disorders and Stroke at the National Institutes of Health, makes MSU’s College of Human Medicine a major player in research of the degenerative disease. Two new MSU researchers, Jack Lipton, Ph.D., and Caryl E. Sortwell, Ph.D.
...[Read more]Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.
...[Read more]Spending time online reduces depression by 20 percent for senior citizens, the Phoenix Center reports in a new Policy Paper released today. In addition to the quality of life benefits, the Policy Paper said reducing the incidence of depression by widespread Internet use among older Americans could trim the nation’s health care bill.
...[Read more]People living close to green space have lower rates of anxiety/depression and poor physical health than those living in concrete jungles, finds research published ahead of print in the Journal of Epidemiology and Community Health. The researchers base their findings on the health records of people registered with 195 family doctors in 95 practices across the Netherlands. Between them, the practices serve a population of almost 350,000.
...[Read more]An innovative diagnostic technique invented by a Monash University researcher could dramatically fast-track the detection of mental and neurological illnesses. Monash biomedical engineer Brian Lithgow has developed electrovestibulography which is something akin to an ‘ECG for the mind’.
...[Read more]